Scientists have developed a new generation of targeted drugs called antibody-drug conjugates (ADCs) with the potential to treat metastatic castrate-resistant prostate cancer. ADCs use the targeting power of antibodies to precisely deliver small amounts of chemotherapy directly to cancer cells. Vobramitamab duocarmazine (also called “vobra duo” is an ADC that targets a protein called B7-H3 found on certain types of cancer cells, including prostate cancer.
Understanding the TAMARACK Clinical Trial for Metastatic Castration Resistant Prostate Cancer (mCRPC)
Overview
The TAMARACK Clinical Trial is studying vobra duo in patients with metastatic castrate-resistant prostate cancer. This is a Phase 2 study and will assess the effectiveness and side effects of two different dose levels of vobra duo.
Who Can Participate
- Adults over 18 years old with metastatic castration-resistant prostate cancer (mCRPC) may be eligible to participate.
- Participants must have received prior treatment with abiraterone, enzalutamide, or apalutamide, have experienced progression of their cancer on or after their most recent cancer treatment, and meet other eligibility criteria.
What’s Involved
- Potential participants will attend one or more screening visits to determine eligibility.
- If eligible, participants will be randomly assigned to one of two different doses of study drug, which they will receive by IV infusion every 4 weeks for up to 2 years.
- Participants will be closely monitored for side effects.
Possible Benefits and Risks
- The use of vobra duo is investigational, meaning its safety and efficacy have not been fully established.
- You may or may not directly benefit from this study. Your participation may help other people with this disease.
- Possible risks of vobra duo include a painful rash on the hands and feet, low blood counts, buildup of fluid around the heart and lungs, or other side effects.
You will need to meet a few other criteria to take part in this study. The study team can explain these to you if you choose to learn more.
Some key eligibility criteria include:
- You must not have been treated with prior chemotherapy other than docetaxel or cabazitaxel.
- If you have a known BRCA or ATM mutation, you must have already been treated with a PARP inhibitor.
The above is not an exhaustive list, for further information please speak to the study doctor.
Organization:
MacroGenics
More information can be found here: TAMARACKStudy.com
Clinicaltrials.gov Information:
- NCT Number: NCT05551117
- Title: A Study of Two Dose Levels of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer (Tamarack)
Use the “clinical trials glossary” and “dictionary” for words, phrases and treatments that you may not understand.
Register your interest or comments about this trial with PHEN
Please Note: This information is provided for educational and awareness purposes. A decision on clinical trials participation is to be made between the patient and his doctor.
This trial is no longer actively recruiting.
